Boston, MA -- (SBWIRE) -- 08/27/2012 -- This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company's historical and forecast financial performance. The report also gives an in-depth analysis of the company's key prescription pharmaceutical product, and provides a forecast sales performance for this drug.

Scope

- Analysis of AMR101 and how it compares with Pronova/GlaxoSmithKline's omega-3 fatty acid product Lovaza
- Discussion of the company's strategy, commercial relationships, and forthcoming catalysts
- Sales forecasts through to 2017
- Financial analysis of the company, including operating performance forecasts through to 2017

View Full Report Details and Table of Contents

Highlights

This report provides forecasts and analysis of Amarin's AMR101. AMR101 is currently being evaluated by the FDA for patients with very high triglycerides, with an expected PDUFA date of July 26, 2012. Amarin also expects to file the drug for approval in patients with high triglycerides in combination with statins within the next year.

Reasons to Get this Report

- Analyze how the performance of AMR101 will shape Amarin's growth prospects
- Understand the current and future market for omega-3 fatty acid agents and how AMR101 will compete for share
- Assess Amarin's potential to partner with another company for the marketing of AMR101

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Amarin Corporation plc (AMRN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Amarin Corporation plc - Product Pipeline Review - H2 2011
- Elan Corporation, plc - Strategy, SWOT, and Corporate Finance Report
- Elan Corporation, plc (ELN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Elan Corporation, plc - Product Pipeline Review - H2 2011
- Elan Corporation, plc - Product Pipeline Review - 2012
- Summit Corporation plc - Product Pipeline Review - H2 2011
- Summit Corporation plc - Product Pipeline Review - Q2 2011
- Elan Corporation, plc (ELN) - Product Pipeline Analysis
- Incyte Corporation: PharmaVitae Report